Updates on the Recognition, Prevention and Management of Hypertension in Pregnancy

Jessica R Jackson; Anthony R Gregg

doi:10.1016/j.ogc.2017.02.007

Updates on the Recognition, Prevention and Management of Hypertension in Pregnancy

Obstet Gynecol Clin North Am. 2017 Jun;44(2):219-230. doi: 10.1016/j.ogc.2017.02.007.

Authors

Jessica R Jackson¹, Anthony R Gregg²

Affiliations

¹ Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Florida College of Medicine, PO Box 100294, Gainesville, FL 32610-0294, USA.
² Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Florida Health System, University of Florida College of Medicine, PO Box 100294, Gainesville, FL 32610-0294, USA. Electronic address: greggar@ufl.edu.

PMID: 28499532
DOI: 10.1016/j.ogc.2017.02.007

Abstract

Systematic reviews with meta-analysis represent the highest level of evidence used to guide clinical practice. The defining criteria used to diagnose preeclampsia have evolved, and will likely continue to evolve. Proteinuria is sufficient but not necessary when defining preeclampsia. Hypertension without proteinuria but with severe features is diagnostic. The methods used to measure urinary protein have changed. The gold standard remains the 24-hour urine test. The efficacy of low-dose aspirin in preventing preeclampsia is a function of baseline risk. Data suggest that treating mild to moderate blood pressure has clear maternal benefits with little fetal or neonatal risk.

Keywords: Aspirin; Criteria; Hypertension; Pregnancy; Proteinuria; Treatment.

Publication types

Review

MeSH terms

Aspirin / therapeutic use
Female
Humans
Hypertension, Pregnancy-Induced / diagnosis*
Hypertension, Pregnancy-Induced / prevention & control
Hypertension, Pregnancy-Induced / therapy*
Platelet Aggregation Inhibitors / therapeutic use
Pregnancy
Pregnancy Complications, Cardiovascular / diagnosis*
Pregnancy Complications, Cardiovascular / therapy*

Substances

Platelet Aggregation Inhibitors
Aspirin